Results 131 to 140 of about 883,247 (168)

Clinical value of CA 19-9 (carbohydrate antigen) in gastrointestinal adenocarcinoma.

The Italian journal of surgical sciences, 1985
CA 19-9 and CEA serum levels were determined before and 7 days after surgery in 140 patients with gastrointestinal adenocarcinoma, and in 70 patients with gastrointestinal non neoplastic diseases. CA 19-9 test was shown to be positive in 37.9% of colorectal cancer, in 32.6% of gastric cancer and in 77.8% of pancreatic cancer.
MENNINI, Giuseppe, SILECCHIA, Gianfranco, C. Zanna, G. Cucchiara, G. Spadaro, E. Greco, BASOLI, Antonio, V. Speranza   +7 more
openaire   +2 more sources

Serum CA 19-9 and CA 50 antigens in hemodialysis patients.

Clinical nephrology, 1987
Serum concentrations of monoclonal antibody-defined tumor markers CA 19-9 and CA 50 were measured in 64 uncomplicated hemodialysis patients (Group 1) and in 8 hemodialysis patients with cancer (Group 2) in comparison with corresponding CEA determinations.
D, Docci, E, Pistocchi, F, Turci, L, Baldrati, S, Urbini, S, Scaioli   +5 more
openaire   +1 more source

Serum CA 125, Carcinoembryonic Antigen, and CA 19-9 as Tumor Markers in Borderline Ovarian Tumors

Gynecologic Oncology, 2000
The goals of this study were to analyze preoperative serum levels of CA 125, carcinoembryonic antigen (CEA), and CA 19-9 in patients with borderline ovarian tumors and to investigate if routine assessment of these markers in follow-up may lead to earlier detection of recurrence.For patient identification a database was used, in which data from all ...
Engelen, MJA, de Bruijn, HWA, Hollema, H, ten Koor, KA, Willemse, PHB, Aalders, JG, van der Zee, AGJ   +6 more
openaire   +3 more sources

The clinical utility of the CA 19-9 tumor-associated antigen.

The American journal of gastroenterology, 1990
Since Koprowski and coworkers discovered the CA 19-9 antigen 10 yr ago, it has become the most useful blood test in the diagnosis and management of patients with cancer of the pancreas. With an upper limit of normal of 37 U/ml, the assay's overall sensitivity is approximately 80% and its specificity is 90%.
openaire   +1 more source

[Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen in gastrointestinal neoplasms. Comparison of markers].

Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma, 1986
CA 19-9, a new antigenic tumor marker for gastrointestinal tumors, has been assayed with Carcinoembriogenic antigen, in 90 healthy patients and 47 patients with gastric cancer (20) and colorectal cancer (27). A good specificity has been found for this antigen (97.7%). Its sensibility seems to be slightly superior to that of CEA. However the sensibility
E, Capocasale, S, Contini, A, Rossetti, G, Del Sante, G, Gregori   +4 more
openaire   +1 more source

[Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer].

Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2002
carcinoembryonic antigen (CEA) was first described more than three decades ago, when its presence was demonstrated in fetal gut tissue and in tumors from gastrointestinal tract. Subsequently, CEA was detected in the circulation of patients and recognized as a serum marker for colorectal cancer.
openaire   +1 more source

Tumour Markers in Uraemia: Carbohydrate Antigen CA 72–4, Carcinoembryonic Antigen and Carbohydrate Antigen CA 19–9

Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1996
L, Fernández-Fernández, M, Asensio, E, Tejero, L, Rabadán, L, Lopez   +4 more
openaire   +2 more sources

Carcinoembryonic antigen (CEA) and gastrointestinal cancer associated antigen CA 19-9 in bronchioloalveolar carcinomas and pulmonary adenocarcinomas.

Annales chirurgiae et gynaecologiae, 1987
The concentrations of carcinoembryonic antigen (CEA) and the gastrointestinal cancer associated antigen CA 19-9 were studied by radioimmunoassay in serum samples from patients with malignant and benign pulmonary tumours. Elevated levels of either markers were found in 14% of patients with malignant tumours and in none of the cases with benign lesions ...
L, Heikkilä, R J, Suomalainen, J, Lindgren, H, Jalanko, A, Harjula, S, Mattila   +5 more
openaire   +1 more source

Integrative oncology: Addressing the global challenges of cancer prevention and treatment

Ca-A Cancer Journal for Clinicians, 2022
Jun J Mao,, Msce, Lorenzo Cohen, Karen M Mustian   +2 more
exaly  

CA 19-9 and Lewis Antigens in Pancreatic Cancer

Journal of Clinical Oncology, 2009
openaire   +2 more sources